Here We Go Again: Another New Therapy For Type 2 Diabetes
Posted January 17, 2013 by John L. Leahy, MD(Full disclosure – I am an Advisor to Janssen pharmaceuticals that makes canagliflozin)
An FDA advisory panel last week reviewed canagliflozin, with the majority recommending approval. Canaglifozin is the first member of a new class of oral medications for type 2 diabetes–sodium-glucose co-transportor-2 (SGLT2) inhibitors–that will likely make it to the U.S. market.